← All diseases Liver, kidneys and digestion

Fatty liver disease (MASH/NASH), advanced

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest evidence only (129)Meta-analysis (42)Randomized Trial (40)Systematic review (32)Phase 3 Study (15)Clinical research (223)Overview article (431)Early study (phase 1 or 2) (12)Laboratory or animal research (274)Single Patient Description (18)Commentary or Editorial (50)Retracted Publication (4) Studies currently seeking participants only (40)

Filter

Publications and studies (2550)

• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database (2025-06-22) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease. (2025-06-18) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH (2025-06-13) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM (2025-06-03) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes (2025-05-25) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH (2025-05-15) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis (2025-05-15) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Hepatic Elastography-Enhanced Lifestyle Modification in MASLD (2025-05-13) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) (2025-05-09) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Optimal Measurement of Spleen Stiffness Among Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease (2025-05-01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. An Observational Study of Inflammatory Bowel Disease (IBD) Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (2025-04-23) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) (2025-04-09) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Evaluate the Effect of Synbiotics on MAFLD (2025-04-03) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study) (2025-04-02) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Effect of CoQ10 on the Outcome of MAFLD Patients (2025-03-26) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population. (2025-03-13) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to Clinical Trials (2025-03-12) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Antidiabetic Drugs for Steatotic Liver Disease (2025-03-05) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) (2025-02-17) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical Classification of MAFLD Based Liver Biopsy (2025-02-12) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study (2025-02-12) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH (2025-02-07) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia (2025-02-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Cardiac Dysfunction in Patients with Fatty Liver Disease (2025-01-29) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis (2025-01-15) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Disease: a Pilot Mechanistic Study (2025-01-13) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) (2025-01-08) ♡
• Association of serum selenium with MASLD and liver fibrosis: A cross-sectional study. (2024/12/31) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). (2024/12/31) ♡
• Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis. (2024/12/31) ♡
• LDHA-Mediated Histone Lactylation Promotes the Nonalcoholic Fatty Liver Disease Progression Through Targeting The METTL3/YTHDF1/SCD1 m6A Axis. (2024/12/31) ♡
• Epigenetic Modulation with 5-Aza-CdR Prevents Metabolic-Associated Fatty Liver Disease Promoted by Maternal Overnutrition. (2024/12/30) ♡
• Endogenous C-type natriuretic peptide offsets the pathogenesis of steatohepatitis, hepatic fibrosis, and portal hypertension. (2024/12/30) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease. (2024/12/30) ♡
• Omentin-1 Mitigates Non-Alcoholic Fatty Liver Disease by Preserving Autophagy Through AMPKα/mTOR Signaling Pathway. (2024/12/28) ♡
• Development of a Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease Prediction in UK Biobank. (2024/12/28) ♡
• Insulin Resistance Mediates the Association Between Vitamin D and Non-Alcoholic Fatty Liver Disease. (2024/12/28) ♡
• Role of AMPKα2 in Regulating the IRE1α-JNK Pathway in Metabolic Dysfunction-Associated Fatty Liver Disease. (2024/12/28) ♡
• Bioinformatics Based Exploration of the Anti-NAFLD Mechanism of Wang's Empirical Formula via TLR4/NF-κB/COX2 Pathway. (2024/12/27) ♡
• Lipophagy and Epigenetic Alterations are Related to Metabolic Dysfunction-Associated Steatotic Liver Disease Progression in an Experimental Model. (2024/12/27) ♡
• Lethal Arrhythmogenic Role of Left Ventricular Myocardial Interstitial Fibrosis in Apolipoprotein E/Low-Density Lipoprotein Receptor Double-Knockout Mice with Metabolic Dysfunction-Associated Steatohepatitis. (2024/12/27) ♡
• Structure-Based Identification of HNF4α Agonists: Rosmarinic Acid as a Promising Candidate for NAFLD Treatment. (2024/12/27) ♡
• Large Annotated Ultrasound Dataset of Non-Alcoholic Fatty Liver from Saudi Hospitals for Analysis and Applications. (2024/12/27) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Influence of Phytosomal Curcumin on Anthropometric Indices for Nonalcoholic Fatty Liver Disease: A Meta-Analysis. (2024/12/27) ♡
• The Effect of Cholecystectomy for Symptomatic Gall Stone Disease on Hepatic Steatosis Using Transabdominal Ultrasonography: An Observational Prospective Study. (2024/12/27) ♡
• A Comprehensive Assessment of Liver Transplant Trends and Outcomes Among Adults With Steatotic Liver Disease in the U.S. (2024/12/27) ♡
• Associations of C-Reactive Protein to Lymphocyte Ratio and Metabolic-Dysfunction-Associated Steatotic Liver Disease: Evidence from NHANES 2017-2018. (2024/12/24) ♡
• Exploring the Link Between Dietary Inflammatory Index and NAFLD Through a Structural Equation Modeling Approach. (2024/12/24) ♡
• The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a predictive indicator of CKD risk in NAFLD patients: NHANES 2017-2020. (2024/12/24) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Holy Basil (Ocimum sanctum L.) Flower and Fenofibrate Improve Lipid Profiles in Rats with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): The Role of Choline Metabolism. (2024/12/24) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.